GenSci161 Injection Clinical Trial Application of Changchun High-Tech Subsidiary Accepted by Regulator

Stock News

08/31

Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) has announced that its majority-owned subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., recently received the official Acceptance Notice issued by the National Medical Products Administration, confirming that the domestic drug registration clinical trial application for the GenSci161 injection has been formally accepted.

Developed independently by Jinsai Pharmaceutical, the GenSci161 injection is a Class 1 therapeutic biological product intended for the treatment of connective tissue disease-associated interstitial lung disease.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1113021196"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113021196\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113021196?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-31 20:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113021196","market":"sh","top_or_hot":-1,"title":"GenSci161 Injection Clinical Trial Application of Changchun High-Tech Subsidiary Accepted by Regulator","media":"Stock News","content":"<p><b>Changchun High-Tech Industry (Group) Co., Ltd.</b> (<b>000661.SZ</b>) has announced that its majority-owned subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., recently received the official Acceptance Notice issued by the National Medical Products Administration, confirming that the domestic drug registration clinical trial application for the GenSci161 injection has been formally accepted.<br><br>Developed independently by Jinsai Pharmaceutical, the GenSci161 injection is a Class 1 therapeutic biological product intended for the treatment of connective tissue disease-associated interstitial lung disease.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GenSci161 Injection Clinical Trial Application of Changchun High-Tech Subsidiary Accepted by Regulator</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenSci161 Injection Clinical Trial Application of Changchun High-Tech Subsidiary Accepted by Regulator\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-31 20:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Changchun High-Tech Industry (Group) Co., Ltd.</b> (<b>000661.SZ</b>) has announced that its majority-owned subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., recently received the official Acceptance Notice issued by the National Medical Products Administration, confirming that the domestic drug registration clinical trial application for the GenSci161 injection has been formally accepted.<br><br>Developed independently by Jinsai Pharmaceutical, the GenSci161 injection is a Class 1 therapeutic biological product intended for the treatment of connective tissue disease-associated interstitial lung disease.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDTX","symbol_name":"Corgi MediaTek 2x Daily ETF","start_time":0,"source_url":"","article_id":"1113021196","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113021196","pubTimestamp":1788179298,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) has announced that its majority-owned subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., recently received the official Acceptance...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDTX":"Corgi MediaTek 2x Daily ETF","BK0046":"生物疫苗","BMED":"iShares Health Innovation Active ETF","BK0028":"国家队","BK0057":"长吉图板块","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BK0239":"医药制造","BK0075":"新三板","000661":"长春高新","BK0188":"融资融券","IBBQ":"Invesco Nasdaq Biotechnology ETF","PSYK":"PSYK ETF"},"translate_title":"长春高新子公司GenSci161注射液临床试验申请获监管机构受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDTX":1,"BMED":1,"PSYK":1,"000661":1,"IBBJ":1,"IBBQ":1},"content_text":"Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) has announced that its majority-owned subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., recently received the official Acceptance Notice issued by the National Medical Products Administration, confirming that the domestic drug registration clinical trial application for the GenSci161 injection has been formally accepted.Developed independently by Jinsai Pharmaceutical, the GenSci161 injection is a Class 1 therapeutic biological product intended for the treatment of connective tissue disease-associated interstitial lung disease.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}